US · ASMB
Assembly Biosciences, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- South San Francisco, CA 94080
- Website
- assemblybio.com
Price · as of 2024-12-31
$27.37
Market cap 256.95M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $814.76 | +2,876.84% |
| Intrinsic Value(DCF) | $2,990.90 | +10,827.66% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $630.00 | ||||
| 2011 | $685.80 | ||||
| 2012 | $201.60 | ||||
| 2013 | $85.20 | ||||
| 2014 | $169.20 | ||||
| 2015 | $67.68 | ||||
| 2016 | $279.96 | ||||
| 2017 | $697.68 | ||||
| 2018 | $218.04 | $20,191.87 | $44.08 | $0.00 | $0.00 |
| 2019 | $247.68 | $99.07 | $42.48 | $0.00 | $0.00 |
| 2020 | $61.68 | $42.13 | $766,792.81 | $0.00 | $0.00 |
| 2021 | $18.12 | $7.25 | $4.92 | $0.00 | $2,875.61 |
| 2022 | $15.00 | $6.00 | |||
| 2023 | $13.58 | $0.00 | $0.00 | ||
| 2024 | $11.12 | $814.76 | $4,244.63 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Assembly Biosciences, Inc.'s (ASMB) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $814.76
- Current price
- $27.37
- AI upside
- +2,876.84%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$2,990.90
+10,827.66% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ASMB | Assembly Biosciences, Inc… | $27.37 | 256.95M | +2,877% | +10,828% | — | — | -1.66 | 2.00 | 2.34 | 0.93 | — | 2.00 | 100.00% | -159.26% | -140.87% | -107.92% | 55.92% | -31.39% | 0.09 | — | 2.42 | 2.35 | 0.78 | -5000.00% | 29816.00% | -32743.00% | -76.60% | -1.07 | 62.97% | 0.00% | 0.00% | 26.59% | 0.93 | 0.83 | -1.48 | -9.57 |
| AARD | Aardvark Therapeutics, In… | $12.49 | 271.95M | — | — | — | — | -6.35 | -2.39 | — | -2.56 | -3.45 | -2.39 | 0.00% | — | — | 46.03% | 26.47% | -46.77% | -0.01 | — | 15.05 | 14.95 | 2.69 | 18393.00% | — | 21243.00% | -13.91% | -3.67 | 21.14% | 0.00% | 0.00% | 39.22% | -2.54 | -3.18 | — | -0.36 |
| ARCT | Arcturus Therapeutics Hol… | $8.23 | 233.85M | +247% | -10% | — | +29% | -4.85 | 1.63 | 2.84 | -2.38 | -2.89 | 1.63 | 100.00% | -69.13% | -58.49% | -31.16% | -388.69% | -20.93% | 0.12 | — | 4.67 | 3.68 | 2.69 | 16786.00% | -1227.00% | 18760.00% | -15.37% | -0.91 | -245.39% | 0.00% | 0.00% | 0.00% | -1.93 | -3.05 | 1.33 | 0.78 |
| ENTA | Enanta Pharmaceuticals, I… | $14.30 | 332M | +189% | -59% | — | — | -3.80 | 4.81 | 4.77 | -4.57 | — | 4.81 | 92.98% | -130.65% | -125.36% | -84.63% | -91.13% | -24.91% | 3.11 | -11.11 | 4.21 | 4.03 | -2.38 | -2993.00% | -342.00% | -6674.00% | -10.33% | -0.40 | -35.04% | 0.00% | 0.00% | 6.44% | -3.79 | -10.06 | 4.96 | -1.26 |
| FHTX | Foghorn Therapeutics Inc. | $5.68 | 332.74M | +360% | -68% | — | +572% | -2.86 | -5.45 | 10.98 | -0.43 | — | -5.45 | 100.00% | -454.31% | -383.24% | 141.17% | 39.62% | -30.40% | -0.82 | — | 3.73 | 3.64 | 0.19 | -3248.00% | -3383.00% | -1510.00% | -40.83% | -1.50 | 39.09% | 0.00% | 0.00% | 0.00% | -0.40 | -0.41 | 1.84 | -2.64 |
| IMRX | Immuneering Corporation | $4.99 | 181.15M | — | — | — | — | -0.75 | 1.10 | — | -0.21 | -8.77 | 1.33 | 0.00% | — | — | -92.51% | -682.42% | -78.61% | 0.10 | — | 5.28 | 4.82 | 0.50 | 851.00% | — | 1171.00% | -120.87% | -7.33 | -586.70% | 0.00% | 0.00% | 0.00% | -0.21 | -0.25 | — | -6.82 |
| NAUT | Nautilus Biotechnology, I… | $2.42 | 305.66M | — | — | — | — | -4.96 | 1.87 | — | -4.18 | — | 1.87 | 0.00% | — | — | -32.27% | -69.30% | -27.20% | 0.19 | — | 13.33 | 13.00 | -0.34 | -1607.00% | — | -1517.00% | -17.74% | -6.38 | -53.89% | 0.00% | 0.00% | 0.05% | -3.28 | -4.22 | — | 2.18 |
| PYXS | Pyxis Oncology, Inc. | $1.47 | 91.53M | — | — | — | — | -0.88 | 0.56 | 4.20 | 0.59 | — | 0.57 | 97.06% | -554.07% | -478.95% | -62.75% | -416.82% | -46.74% | 0.17 | — | 7.49 | 7.18 | -0.01 | -2865.00% | — | -2522.00% | -85.42% | -3.26 | -277.36% | 0.00% | 0.00% | 16.14% | 0.44 | 0.67 | -2.41 | -3.02 |
| SGMT | Sagimet Biosciences Inc. | $5.71 | 177.02M | +358% | — | — | — | -2.53 | 0.74 | — | 0.79 | — | 0.74 | 0.00% | — | — | -36.92% | -12575.98% | -35.46% | 0.00 | — | 34.30 | 33.96 | 1.66 | -523.00% | -10000.00% | 7855.00% | -36.78% | -9.53 | -9800.23% | 0.00% | 0.00% | 0.60% | 0.66 | 0.84 | — | 12.95 |
| TNYA | Tenaya Therapeutics, Inc. | $0.56 | 93.6M | — | — | — | — | -0.35 | 0.42 | — | 0.09 | — | 0.42 | 0.00% | — | — | -95.69% | -251.45% | -76.52% | 0.15 | — | 4.22 | 3.85 | -0.09 | -2202.00% | — | -1141.00% | -237.15% | -5.67 | -198.49% | 0.00% | 0.00% | 0.00% | 0.08 | 0.10 | — | -7.83 |
| ZURA | Zura Bio Limited | $6.62 | 430.45M | — | — | — | — | -1.81 | 0.64 | — | 1.48 | — | 0.64 | 0.00% | — | — | -50.84% | 157.33% | -37.38% | 0.00 | — | 9.16 | 9.04 | 3.20 | -7129.00% | — | 2211.00% | -29.76% | -1.44 | 80.25% | 0.00% | 0.00% | 81.08% | 1.48 | 2.91 | — | 1.74 |
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
- CEO
- Jason A. Okazaki
- Employees
- 73
- Beta
- 1.15
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($2,990.90 ÷ $27.37) − 1 = +10,827.66% (DCF, example).